LIFE Trial: sacubitril/valsartan combination not effective to treat HF

Published On 2022-02-11 13:31 GMT   |   Update On 2022-02-16 11:54 GMT
Advertisement

The LIFE trial highlights that combination sacubitril/valsartan did not reduce N-terminal pro b-type natriuretic peptide (NT-proBNP) or clinical outcomes among patients with advanced heart failure with reduced ejection fraction and comorbidities. Heart failure can develop suddenly or over time causing cardiac death which is a leading cause of death globally. Several medications are being evaluated to manage heart failure.

Advertisement

The trial aimed to assess the efficacy and safety of sacubitril/valsartan compared with valsartan in patients with advanced heart failure with reduced ejection fraction. 167 patients were randomized in a 1:1 ratio to either sacubitril/valsartan starting dose 24/26 mg or 49/51 mg twice a day, to 97/103 mg increased twice a day if tolerated after 4 weeks, or valsartan starting dose 40 or 80 mg twice a day.

Drugs didn't improve mortality and cardiovascular events, days alive outside hospital was 103.2 vs. 111.2 days, published in American College of Cardiology the results of this trial indicate that the combination sacubitril/valsartan did not reduce NT-proBNP or clinical outcomes among patients with advanced heart failure with reduced ejection fraction and comorbidities.

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News